vs
Side-by-side financial comparison of LPL Financial Holdings Inc. (LPLA) and TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA). Click either name above to swap in a different company.
LPL Financial Holdings Inc. is the larger business by last-quarter revenue ($4.9B vs $4.7B, roughly 1.0× TEVA PHARMACEUTICAL INDUSTRIES LTD). TEVA PHARMACEUTICAL INDUSTRIES LTD runs the higher net margin — 10.2% vs 6.1%, a 4.1% gap on every dollar of revenue. On growth, LPL Financial Holdings Inc. posted the faster year-over-year revenue change (40.4% vs 11.4%). TEVA PHARMACEUTICAL INDUSTRIES LTD produced more free cash flow last quarter ($1.0B vs $613.3M). Over the past eight quarters, LPL Financial Holdings Inc.'s revenue compounded faster (32.0% CAGR vs 11.1%).
LPL Financial Holdings Inc. was founded in 1989 and is considered the largest independent broker-dealer in the United States. As of 2021 the company had more than 17,500 financial advisors, over US$1 trillion in advisory and brokerage assets, and generated approximately $10.3 billion in annual revenue for the 2023 fiscal year. LPL Financial has main offices in Boston, Fort Mill, Austin, and San Diego. The company is a member of FINRA and the SIPC.
Teva Pharmaceutical Industries Ltd. is an Israeli multinational pharmaceutical company. Teva specializes primarily in generic drugs, but other business interests include branded-drugs, active pharmaceutical ingredients (APIs) and, to a lesser extent, contract manufacturing services and an out-licensing platform.
LPLA vs TEVA — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $4.9B | $4.7B |
| Net Profit | $300.7M | $481.0M |
| Gross Margin | — | 56.4% |
| Operating Margin | 8.1% | 6.4% |
| Net Margin | 6.1% | 10.2% |
| Revenue YoY | 40.4% | 11.4% |
| Net Profit YoY | 11.1% | 321.7% |
| EPS (diluted) | $3.65 | $0.42 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $4.9B | $4.7B | ||
| Q3 25 | $4.6B | $4.5B | ||
| Q2 25 | $3.8B | $4.2B | ||
| Q1 25 | $3.7B | $3.9B | ||
| Q4 24 | $3.5B | $4.2B | ||
| Q3 24 | $3.1B | $4.3B | ||
| Q2 24 | $2.9B | $4.2B | ||
| Q1 24 | $2.8B | $3.8B |
| Q4 25 | $300.7M | $481.0M | ||
| Q3 25 | $-29.5M | $433.0M | ||
| Q2 25 | $273.2M | $282.0M | ||
| Q1 25 | $318.6M | $214.0M | ||
| Q4 24 | $270.7M | $-217.0M | ||
| Q3 24 | $255.3M | $-437.0M | ||
| Q2 24 | $243.8M | $-846.0M | ||
| Q1 24 | $288.8M | $-139.0M |
| Q4 25 | — | 56.4% | ||
| Q3 25 | — | 51.4% | ||
| Q2 25 | — | 50.3% | ||
| Q1 25 | — | 48.2% | ||
| Q4 24 | — | 50.2% | ||
| Q3 24 | — | 49.6% | ||
| Q2 24 | — | 48.6% | ||
| Q1 24 | — | 46.4% |
| Q4 25 | 8.1% | 6.4% | ||
| Q3 25 | -0.7% | 19.7% | ||
| Q2 25 | 9.6% | 10.9% | ||
| Q1 25 | 11.4% | 13.3% | ||
| Q4 24 | 9.7% | -0.7% | ||
| Q3 24 | 11.2% | -1.2% | ||
| Q2 24 | 11.3% | -0.1% | ||
| Q1 24 | 13.2% | -5.7% |
| Q4 25 | 6.1% | 10.2% | ||
| Q3 25 | -0.6% | 9.7% | ||
| Q2 25 | 7.1% | 6.8% | ||
| Q1 25 | 8.7% | 5.5% | ||
| Q4 24 | 7.7% | -5.1% | ||
| Q3 24 | 8.2% | -10.1% | ||
| Q2 24 | 8.3% | -20.3% | ||
| Q1 24 | 10.2% | -3.6% |
| Q4 25 | $3.65 | $0.42 | ||
| Q3 25 | $-0.37 | $0.37 | ||
| Q2 25 | $3.40 | $0.24 | ||
| Q1 25 | $4.24 | $0.18 | ||
| Q4 24 | $3.58 | $-0.19 | ||
| Q3 24 | $3.39 | $-0.39 | ||
| Q2 24 | $3.23 | $-0.75 | ||
| Q1 24 | $3.83 | $-0.12 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $1.1B | $3.6B |
| Total DebtLower is stronger | $7.3B | — |
| Stockholders' EquityBook value | $5.3B | $7.9B |
| Total Assets | $18.5B | $40.7B |
| Debt / EquityLower = less leverage | 1.36× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $1.1B | $3.6B | ||
| Q3 25 | $1.6B | $2.2B | ||
| Q2 25 | $4.3B | $2.2B | ||
| Q1 25 | $1.4B | $1.7B | ||
| Q4 24 | $1.0B | $3.3B | ||
| Q3 24 | $1.6B | $3.3B | ||
| Q2 24 | $1.4B | $2.3B | ||
| Q1 24 | $1.2B | $3.0B |
| Q4 25 | $7.3B | — | ||
| Q3 25 | $7.5B | — | ||
| Q2 25 | $7.2B | — | ||
| Q1 25 | $5.7B | — | ||
| Q4 24 | $5.5B | — | ||
| Q3 24 | $4.4B | — | ||
| Q2 24 | $4.4B | — | ||
| Q1 24 | $3.9B | — |
| Q4 25 | $5.3B | $7.9B | ||
| Q3 25 | $5.0B | $7.3B | ||
| Q2 25 | $5.1B | $6.8B | ||
| Q1 25 | $3.1B | $6.3B | ||
| Q4 24 | $2.9B | $5.4B | ||
| Q3 24 | $2.8B | $6.1B | ||
| Q2 24 | $2.5B | $6.4B | ||
| Q1 24 | $2.3B | $7.3B |
| Q4 25 | $18.5B | $40.7B | ||
| Q3 25 | $18.0B | $39.9B | ||
| Q2 25 | $17.5B | $40.1B | ||
| Q1 25 | $14.0B | $38.4B | ||
| Q4 24 | $13.3B | $39.3B | ||
| Q3 24 | $11.9B | $41.8B | ||
| Q2 24 | $11.5B | $41.3B | ||
| Q1 24 | $11.0B | $42.8B |
| Q4 25 | 1.36× | — | ||
| Q3 25 | 1.49× | — | ||
| Q2 25 | 1.41× | — | ||
| Q1 25 | 1.82× | — | ||
| Q4 24 | 1.87× | — | ||
| Q3 24 | 1.60× | — | ||
| Q2 24 | 1.77× | — | ||
| Q1 24 | 1.70× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $785.0M | $1.2B |
| Free Cash FlowOCF − Capex | $613.3M | $1.0B |
| FCF MarginFCF / Revenue | 12.4% | 21.6% |
| Capex IntensityCapex / Revenue | 3.5% | 3.0% |
| Cash ConversionOCF / Net Profit | 2.61× | 2.41× |
| TTM Free Cash FlowTrailing 4 quarters | $-981.8M | $1.1B |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $785.0M | $1.2B | ||
| Q3 25 | $-1.7B | $369.0M | ||
| Q2 25 | $193.3M | $227.0M | ||
| Q1 25 | $339.8M | $-105.0M | ||
| Q4 24 | $-178.8M | $575.0M | ||
| Q3 24 | $209.3M | $693.0M | ||
| Q2 24 | $-178.9M | $103.0M | ||
| Q1 24 | $425.9M | $-124.0M |
| Q4 25 | $613.3M | $1.0B | ||
| Q3 25 | $-1.9B | $233.0M | ||
| Q2 25 | $56.3M | $131.0M | ||
| Q1 25 | $220.3M | $-232.0M | ||
| Q4 24 | $-344.3M | $446.0M | ||
| Q3 24 | $62.3M | $545.0M | ||
| Q2 24 | $-307.8M | $6.0M | ||
| Q1 24 | $304.9M | $-248.0M |
| Q4 25 | 12.4% | 21.6% | ||
| Q3 25 | -41.1% | 5.2% | ||
| Q2 25 | 1.5% | 3.1% | ||
| Q1 25 | 6.0% | -6.0% | ||
| Q4 24 | -9.8% | 10.5% | ||
| Q3 24 | 2.0% | 12.6% | ||
| Q2 24 | -10.5% | 0.1% | ||
| Q1 24 | 10.8% | -6.5% |
| Q4 25 | 3.5% | 3.0% | ||
| Q3 25 | 3.1% | 3.0% | ||
| Q2 25 | 3.6% | 2.3% | ||
| Q1 25 | 3.3% | 3.3% | ||
| Q4 24 | 4.7% | 3.1% | ||
| Q3 24 | 4.7% | 3.4% | ||
| Q2 24 | 4.4% | 2.3% | ||
| Q1 24 | 4.3% | 3.2% |
| Q4 25 | 2.61× | 2.41× | ||
| Q3 25 | — | 0.85× | ||
| Q2 25 | 0.71× | 0.80× | ||
| Q1 25 | 1.07× | -0.49× | ||
| Q4 24 | -0.66× | — | ||
| Q3 24 | 0.82× | — | ||
| Q2 24 | -0.73× | — | ||
| Q1 24 | 1.47× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
LPLA
Segment breakdown not available.
TEVA
| Other | $2.0B | 42% |
| Generics Medicians Including Otc And Biosimilars | $672.0M | 14% |
| Other Products | $608.0M | 13% |
| License | $529.0M | 11% |
| Distribution Service | $366.0M | 8% |
| Other Activities | $227.0M | 5% |
| Ajovy | $106.0M | 2% |
| COPAXONE | $77.0M | 2% |
| Respiratory Product | $65.0M | 1% |
| Uzedy | $55.0M | 1% |
| Bendeka And Treanda | $36.0M | 1% |
